Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 8/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338485 | 0.91 | S1PR1 (0.37) | S1PR1S1PR3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1743669 | 0.90 | PIK3CD (0.32) | S1PR1S1PR3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1338064 | 0.89 | HDAC4 (0.36) | S1PR1S1PR3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1743666 | 0.88 | S1PR1 (0.35) | S1PR1S1PR3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1742465 | 0.84 | S1PR1 (0.33) | S1PR1S1PR3 | |
| SCHEMBL2475185 | 0.82 | S1PR1 (0.32) | S1PR1S1PR3 | |
| SCHEMBL1742464 | 0.81 | S1PR1 (0.37) | S1PR1S1PR3 | |
| SCHEMBL1337433 | 0.79 | S1PR1 (0.38) | S1PR1S1PR3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1337948 | 0.78 | S1PR1 (0.40) | S1PR1S1PR3BDKRB1 | |
| SCHEMBL13263464 | 0.77 | S1PR1 (0.39) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| EP-2210890-A1 | Oxadiazole derivatives as S1P1 receptor agonists | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885PIK3CD 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.